Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and lowers the price target from $33 to $30.
Traders Speculate Circulation Of Tweet Of Ocular Therapeutix Presentation Today At AAO; Shares Spike Higher
https://twitter.com/buysidebio/status/1575568356823822336